Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapa-RHF
2024-515044-23-01Phase 2Authorised
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Right heart dysfunction (RHF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in serum NT-proBNP level from baseline to end of treatment (Delta-NT-proBNP). Planned start Aug 2024; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
Right heart dysfunction (RHF)
Beyond the preview
Go deeper on 2024-515044-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515044-23-01.